MDCXW

Medicus Pharma Ltd. (NASDAQ:MDCXW) is a clinical-stage biotechnology company that went public in November 2024. Founded as a holding company focused on accelerating the development of novel therapeutic assets, Medicus operates primarily through its lead subsidiary, SkinJect Inc. The company is developing innovative treatments for cancer, specifically targeting basal cell carcinoma through non-invasive delivery methods. As a recently public biotech company, Medicus is in the early stages of clinical development with no current revenue generation.